JPRN-UMIN000005848招募中未知
Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness - Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with contraindiation for the use of the drugs
研究者
相似试验
招募中
不适用
Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectivenesshepatocellular carcinomaJPRN-UMIN000005847Kyoto university hospital50
招募中
2 期
To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007488ippon medical school100
进行中（未招募）
不适用
Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial - BOOSTadvanced hepatocellular carcinoma with ChildPugh liver function class BMedDRA version: 9.1Level: LLTClassification code 10024720EUCTR2009-013870-42-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
Unknown
2 期
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular CarcinomaPHENYTOIN/SORAFENIB [VA Drug Interaction]Carcinoma, HepatocellularNCT01605734Shandong Cancer Hospital and Institute120
已完成
不适用
Comparison of Sorafenib and DEB-TACE in patients wth hepatocellular carcinoma refractory to conventional TACE.hepatocellular carcinomaJPRN-UMIN000014999Musashino Red Cross Hospital100